Cardiology

First and currently only biological targeting P-selectin.

Statin regimens may need tweaking to deliver optimal results. 

Approved in May 2019, granted to FoldRx, a subsidiary of Pfizer.

Reduces risk for heart failure and cardiovascular disease hospitalizations.

Also indciated to control bleeding and perioperative management.

Black box warns of increased risk of blood clots and death.

Fourth approval for use in assessing myocardial perfusion and late gadolinium enhancement.

Type 2 diabetes mellitus is a risk factor for incident heart failure, according to a new scientific statement from the American Heart Association (AHA), and it increases the risk of morbidity and mortality in patients with established disease.

Study finds higher Ischemic events and mortality in transcatheter valve replacement patients taking non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists.

Low-risk atrial fibrillation patients who take oral anticoagulants have a lower risk of dementia than those who do not, a study says.

The use of direct‐acting oral anticoagulants has increased among nursing home residents with atrial fibrillation.

Overestimating the bleeding risk of anticoagulants may lead to poor compliance.

Fragmin, a low-molecular-weight heparin dalteparin sodium injection, was approved for symptomatic venous thromboembolism.

Two different versions of tafamadis get the FDA’s nod to treat a rare heart disease. 

Bleeding in patients with nonvalvular atrial fibrillation and coronary syndrome was reduced by apixaban versus vitamin K antagonists.

Many kidney disease patients with atrial fibrillation are not treated with anticoagulation, increasing their risk of stroke.

Study finds different anticoagulation treatment levels for patients with cognitive problems.

A meta-analysis of 95 studies indicates lower risk of stroke and intracranial hemorrhage.

Higher-dose tofacitinib linked to greater risk of pulmonary embolism in RA patients.

What you need to know about the von Willebrand factor (vWF)-directed antibody fragment.

DOACs are as good as warfarin in preventing atrial fibrillation complications.

Three cardiology groups now recommend using NOACs over warfarin in atrial fibrillation.

Black patients with atrial fibrillation are less likely to be treated with oral anticoagulants or DOACs.

The risk of gastrointestinal bleeding appears to be highest with rivaroxaban and lowest with apixaban, but is reduced by cotherapy with proton pump inhibitors.

Patients with atrial fibrillation who have had cancer are less likely to see a cardiologist and less likely to fill anticoagulant prescriptions.